PRIMARY MYELOFIBROSIS
Clinical trials for PRIMARY MYELOFIBROSIS explained in plain language.
Never miss a new study
Get alerted when new PRIMARY MYELOFIBROSIS trials appear
Sign up with your email to follow new studies for PRIMARY MYELOFIBROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Drug added to transplant shows promise for blood cancer patients
Disease control OngoingThis study is testing whether adding the drug ruxolitinib before, during, and after a stem cell transplant can improve results for people with myelofibrosis, a serious bone marrow cancer. The transplant is currently the only treatment with potential to cure the disease, but it ca…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 04, 2026 00:06 UTC
-
New hope for tough blood cancer cases: two drugs join forces
Disease control OngoingThis study is testing whether combining two drugs, fedratinib and nivolumab, can help control myelofibrosis, a serious bone marrow cancer. It is for patients whose disease did not respond well enough to standard JAK inhibitor medications. The goal is to see if this combination ca…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New drug trial aims to shrink enlarged spleens in blood cancer patients
Disease control OngoingThis study is testing a drug called fedratinib in Japanese adults with a serious bone marrow cancer called myelofibrosis. The goal is to find a safe and effective dose that can reduce spleen size and ease symptoms like fatigue and abdominal discomfort. Participants will take the …
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 02, 2026 14:56 UTC
-
New drug trial targets scarring bone marrow disease
Disease control OngoingThis study is testing if a drug called elotuzumab can help control myelofibrosis, a rare blood cancer that causes bone marrow scarring. The trial will involve about 15 adults with a specific genetic change (JAK2 mutation) who are not candidates for standard JAK inhibitor therapy.…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Patients continue life-extending blood cancer drugs in safety study
Disease control OngoingThis study allows patients who benefited from previous clinical trials of ruxolitinib (alone or with panobinostat) to continue receiving their treatment while researchers monitor long-term safety. The study includes 279 patients with various blood conditions like myelofibrosis an…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for blood cancer patients: Two-Drug combo aims to tame disease
Disease control OngoingThis large, late-stage trial is testing whether adding a new drug called pelabresib to the standard treatment (ruxolitinib) works better for people newly diagnosed with myelofibrosis, a serious bone marrow cancer. The study will see if the combination shrinks enlarged spleens mor…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: PRIMARY MYELOFIBROSIS
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New Two-Part strategy aims to tame bone marrow cancer before transplant
Disease control OngoingThis study is testing a two-step treatment for myelofibrosis, a serious bone marrow cancer. First, patients take a JAK inhibitor drug (ruxolitinib) for at least 8 weeks to try to reduce symptoms and improve their health. Then, they receive a stem cell transplant from a donor, whi…
Matched conditions: PRIMARY MYELOFIBROSIS
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Mar 09, 2026 14:22 UTC